Citigroup Inc Arrowhead Pharmaceuticals, Inc. Call Options Transaction History

Citigroup Inc

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 12, 2024	BUY	$21.87 - $28.24 $463,644 - $598,688	21,200 Added 85.14%	46,100 $1.2 Million
Q1 2024 May 10, 2024	BUY	$27.21 - $39.48 $193,191 - $280,308	7,100 Added 39.89%	24,900 $712,000
Q4 2023 Feb 09, 2024	BUY	$21.2 - $31.03 $377,360 - $552,334	17,800 New	17,800 $544,000
Q2 2023 Aug 10, 2023	SELL	$25.16 - $41.38 $123,284 - $202,762	-4,900 Reduced 8.19%	54,900 $1.96 Million
Q1 2023 May 11, 2023	BUY	$23.68 - $38.51 $279,424 - $454,418	11,800 Added 24.58%	59,800 $1.52 Million
Q4 2022 Feb 09, 2023	BUY	$28.0 - $40.56 $504,000 - $730,080	18,000 Added 60.0%	48,000 $1.95 Million
Q2 2022 Aug 10, 2022	BUY	$27.79 - $50.61 $833,700 - $1.52 Million	30,000 New	30,000 $1.06 Million

294

90.8M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.07B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.